{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:33:28Z","timestamp":1786743208317,"version":"build-2736575974"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100007033","name":"Eisai Korea Inc.","doi-asserted-by":"publisher","award":["JYS-IIS-M082-1006"],"award-info":[{"award-number":["JYS-IIS-M082-1006"]}],"id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal sequencing of advanced therapy in ulcerative colitis (UC) remains unclear. Data comparing different sequencing including the use of tofacitinib as first-line therapy remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We compared the treatment persistence of two therapeutic strategies: anti-tumor necrosis factor (anti-TNF) agents to tofacitinib (A\u2192T) versus tofacitinib to anti\u2013TNF agents (T\u2192A).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We conducted a retrospective, nationwide, claims-based cohort study using data from the Korean Health Insurance Review and Assessment database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included adult UC patients initiating anti-TNF agents or tofacitinib as first-line therapy. The primary outcome was second-line treatment persistence, using Kaplan-Meier method and multivariable Cox models to estimate adjusted hazard ratios (aHRs). Propensity score matching balanced baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 314 patients were included (A\u2192T, n=273; T\u2192A, n=41). The T\u2192A group was younger (33.0 vs 42.0 years; P=0.02), had lower concomitant use of corticosteroids at first-line therapy (36.59% vs 65.57%; P&lt;0.01), and had shorter duration of total advanced therapy (3.50 vs 4.29 years; P&lt;0.01). After propensity score matching, the persistence of second-line therapy was significantly longer in the A\u2192T group compared with the T\u2192A group (aHR, 2.48; 95% CI, 1.18\u20135.21; P=0.02), whereas the persistence of first-line therapy did not differ significantly between the two sequences (aHR, 1.18; 95% CI, 0.76\u20131.85; P=0.46). Progression to third-line therapy occurred more frequently in the T\u2192A group than in the A\u2192T group (41.5% vs 19.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Korean UC patients, switching from anti-TNF agents to tofacitinib was associated with longer second-line treatment persistence than the reverse sequence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261478114","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:29:41Z","timestamp":1786490981000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5272-4293","authenticated-orcid":false,"given":"Ji Eun","family":"Baek","sequence":"first","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arum","family":"Choi","sequence":"additional","affiliation":[{"name":"Asan Medical Center"},{"name":"University of Ulsan College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-In","family":"Lee","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-4553","authenticated-orcid":false,"given":"Kang-Moon","family":"Lee","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030747"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz001"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.078"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.005"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.01.035"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.011"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.10.001"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30265-6"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.5.718"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.20.0062"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000503859"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae188"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy322"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315671"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393463"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab011"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00127"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2022.00007"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231154103"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.017"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2106216"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad115"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad245"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00148"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-04022-7"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00118"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2249237"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2025.00309"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261478114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261478114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261478114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:59:10Z","timestamp":1786741150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261478114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"alternative-id":["10.1177\/17562848261478114"],"URL":"https:\/\/doi.org\/10.1177\/17562848261478114","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261478114"}}